BACE1 and Alzheimer disease: Ginsenoside Rg1 (Figure 2), especially proven as noticeable extracts compounds for the ingredients of AD treatments, mainly targets the activation of the transcription factor PPAR-γ through binding to the BACE1 promoter instead of BACE1, eventually leading to the prevention of the formation of toxic Aβ aggregates.